Abstract RAS mutations (HRAS, NRAS, and KRAS) are among the most common
oncogenes, and around 19% of patients with cancer harbor RAS mutations. Cells harboring …

In June 2022, the FDA granted Accelerated Approval to the BRAF inhibitor dabrafenib in
combination with the MEK inhibitor trametinib for the treatment of adult and paediatric …

KRAS is the most frequent oncogene in non-small cell lung cancer (NSCLC), a molecular
subset characterized by historical disappointments in targeted treatment approaches such …

Oncogenic mutations in the small GTPase KRAS are frequently found in human cancers,
and, currently, there are no effective targeted therapies for these tumors. Using a …

Purpose: Targeting RAF for antitumor therapy in RAS-mutant tumors holds promise. Herein,
we describe in detail novel properties of the type II RAF inhibitor, LXH254. Experimental …

MAPK targeting in cancer often fails due to MAPK reactivation. MEK inhibitor (MEKi)
monotherapy provides limited clinical benefits but may serve as a foundation for …

Serine/threonine-protein kinase B-Raf (BRAF; RAF= rapidly accelerated fibrosarcoma) plays
an important role in the mitogen-activated protein kinase (MAPK) signaling cascade …

The clinical significance of gene fusions detected by DNA-based next generation
sequencing remains unclear as resistance mechanisms to EGFR tyrosine kinase inhibitors …

FGFR1 was recently shown to be activated as part of a compensatory response to prolonged
treatment with the MEK inhibitor trametinib in several KRAS-mutant lung and pancreatic …

Assembly of RAS molecules into complexes at the cell membrane is critical for RAS
signaling. We previously showed that oncogenic KRAS codon 61 mutations increase its …